Initiative aims to replace animal models for drug development
A new UK initiative is aiming to transform human-based research models to provide better understanding of disease and accelerate new medicines.
The UKRI Medical Research Council (MRC), Wellcome and UKRI Innovate UK committed a joint £15.9 million ($20.9 million) investment to develop advanced, specific and highly reproducible human in vitro models. These models will become available to researchers in academia and industry.
A co-ordinated network of five interdisciplinary teams will work on the development of in vitro disease models of the liver, brain, cancer, pain and blood vessels.
These models will provide new alternatives for researchers, helping to reduce the reliance on animal models in research and drug development. This will align with the UK government’s strategy ‘Replacing animals in science’, announced today.
Professor Patrick Chinnery, MRC Executive Chair, said the initiative represents “a major step forward in our commitment to developing innovative, non-animal methods.”
“Human in vitro models enable the investigation of disease mechanisms whilst minimising the use of animals,” he commented. “This will accelerate our ability to diagnose illnesses early, develop new treatments, and prevent disease.”
How in vitro models could develop better treatments
In vitro models use isolated cells and tissues outside the living body. This includes stem-cell derived cell and tissue aggregates displaying some organ features on a smaller scale (organoids), tissue slices removed during surgery, and organ-on-chips, which combine cell culture with microfluidics to mimic the structure and function of different organ tissues.
“These novel human in vitro models will help accelerate discovery research by enabling better understanding of fundamental human physiology and disease,” said Dr Michael Dunn, Director of Discovery Research at Wellcome.
“We’re pleased to partner with UKRI MRC and Innovate UK to support the development and uptake of these exciting models, which can potentially underpin the development of new and better treatments for a range of diseases.”
Tom Adeyoola, Innovate UK Executive Chair, added: “We’re backing scalable human tissue models so companies can get involved early, help shape the technology, and position themselves for global markets.
“It means better science, less animal testing and real commercial opportunities down the line. That’s exactly why Innovate UK is supporting it.”
Bruno Quinney, Content Team, DDW
